<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243320</url>
  </required_header>
  <id_info>
    <org_study_id>40281</org_study_id>
    <nct_id>NCT01243320</nct_id>
  </id_info>
  <brief_title>In Vivo Assessment of Silver Biomaterial Nano-Toxicity</brief_title>
  <official_title>In Vivo Assessment of Silver Biomaterial Nano-Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nanotechnology is the controlled generation and manipulation of matter in dimensions less
      than 100 nm. Silver has been used for its bactericidal properties. The investigators propose
      to study the American Biotech Laboratory 32 ppm silver solution over a 14-day period in human
      volunteers to determine the toxicity and to quantify cytochrome P450 enzyme effects of this
      solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sodium Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Potassium Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Chloride Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Carbon Dioxide Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urea Nitrogen Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In CreatinineBlood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Glucose Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Alkaline Phosphatase Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Aspartate Aminotransferase Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Alanine Aminotransferase Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Total Protein Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Total Bilirubin Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Albumin Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Calcium Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In White Blood Count Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Red Blood Count Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Hemoglobin Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Hematocrit Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Mean Corpuscular Volume Blood Levels</measure>
    <time_frame>14 days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Mean Corpuscular Hemoglobin Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Mean Corpuscular Hemoglobin Concentration Blood Levels</measure>
    <time_frame>14 days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Platelet Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Granulocytes Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Lymphocytes Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Monocytes Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Basophils Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Eosinophil Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum Reactive Oxygen Species Change</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change to Interleukin-8 Receptor</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change to Interleukin-1 Alpha Receptor</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change to Interleukin-1 Beta Receptor</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Monocyte Chemotactic Protein 1</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quinone Oxidoreductase 1 Gene</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Systolic Blood Pressure</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Diastolic Blood Pressure</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Heart Rate</measure>
    <time_frame>14 Days</time_frame>
    <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>10ppm Oral Silver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Dose of 10ppm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>32ppm Oral Silver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Dose of 32ppm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10ppm Oral Silver Particle</intervention_name>
    <description>Silver nanoparticles at 10ppm</description>
    <arm_group_label>10ppm Oral Silver</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>32ppm Oral Silver Particle</intervention_name>
    <description>Silver nanoparticles at 32ppm</description>
    <arm_group_label>32ppm Oral Silver</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be &gt; 18-80 years old will be included.

        Exclusion Criteria:

          -  Females of child-bearing potential, defined as women physically capable of becoming
             pregnant, including women whose career, lifestyle, or sexual orientation precludes
             intercourse with a male partner and women whose partners have been sterilized by
             vasectomy or other means will be excluded unless they are using 2 barrier birth
             control methods (i.e., diaphragm, condom, intrauterine device, sponge or spermicide)
             or hormonal contraceptive method.

          -  Any female subject who is nursing will be excluded. Subject with has a history of
             heavy metal allergy (including silver) or a history of asthma or COPD or renal
             impairment defined by a creatinine clearance below 30 ml/min.

          -  Subjects with symptoms of an active upper respiratory infection at time of consent
             will also be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Munger, Pharm.D&gt;</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Hospital and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <results_first_submitted>June 4, 2015</results_first_submitted>
  <results_first_submitted_qc>July 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2015</results_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>mark munger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Study had two dosing phases. All study participants were assigned the 10ppm Oral Silver and proceed to the 32 pm Oral Silver.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>10ppm Oral Silver (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>10ppm Oral Silver (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>10ppm Oral Silver (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>32ppm Oral Silver (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>10 ppm Silver, then 32 ppm Silver</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change Systolic Blood Pressure</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change Systolic Blood Pressure</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mmhg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-1.7" upper_limit="4.3"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-3.0" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Diastolic Blood Pressure</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Diastolic Blood Pressure</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mmhg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-5.5" upper_limit="0.7"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-2.5" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Heart Rate</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Heart Rate</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-5.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="-3.1" lower_limit="-6.4" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sodium Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sodium Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.7" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.7" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Potassium Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Potassium Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.3" upper_limit="0.02"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.2" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Chloride Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Chloride Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-1.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Carbon Dioxide Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Carbon Dioxide Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-0.5" upper_limit="1.6"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-1.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urea Nitrogen Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urea Nitrogen Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-1.7" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-0.08" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In CreatinineBlood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In CreatinineBlood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.02" upper_limit="0.03"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.04" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Glucose Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Glucose Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="-1.6" upper_limit="8.7"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-4.2" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Alkaline Phosphatase Blood Level</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Alkaline Phosphatase Blood Level</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>u/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-3.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Aspartate Aminotransferase Blood Level</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Aspartate Aminotransferase Blood Level</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>u/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" lower_limit="-2.1" upper_limit="1.2"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-2.6" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Alanine Aminotransferase Blood Level</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Alanine Aminotransferase Blood Level</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>u/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-4.8" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="2.3" lower_limit="-1.6" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Total Protein Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Total Protein Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.001" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Total Bilirubin Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Total Bilirubin Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.08" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.11" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Albumin Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Albumin Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-0.1" upper_limit="0.0004"/>
                    <measurement group_id="O2" value="0.11" lower_limit="-0.01" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Calcium Blood Level</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Calcium Blood Level</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.2" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.003" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In White Blood Count Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In White Blood Count Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>k/uL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-0.53" upper_limit="0.19"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-0.68" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Red Blood Count Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Red Blood Count Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>m/uL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-0.17" upper_limit="-0.0001"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.03" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Hemoglobin Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Hemoglobin Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.4" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Hematocrit Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Hematocrit Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-1.5" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0.8" lower_limit="-0.1" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Mean Corpuscular Volume Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Mean Corpuscular Volume Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.6" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Mean Corpuscular Hemoglobin Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Mean Corpuscular Hemoglobin Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>pg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.1" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.4" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Mean Corpuscular Hemoglobin Concentration Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Mean Corpuscular Hemoglobin Concentration Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.3" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-0.7" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Platelet Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Platelet Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>k/uL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-6" upper_limit="15"/>
                    <measurement group_id="O2" value="-4" lower_limit="-16" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Granulocytes Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Granulocytes Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-3.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-4.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Lymphocytes Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Lymphocytes Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-1.2" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-1.5" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Monocytes Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Monocytes Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.6" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-0.8" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Basophils Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Basophils Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.001" lower_limit="-0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Eosinophil Blood Levels</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eosinophil Blood Levels</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.7" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum Reactive Oxygen Species Change</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Reactive Oxygen Species Change</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="-0.6" upper_limit="2.38"/>
                    <measurement group_id="O2" value="-0.44" lower_limit="-1.23" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change to Interleukin-8 Receptor</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change to Interleukin-8 Receptor</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="-1.53" upper_limit="5.9"/>
                    <measurement group_id="O2" value="6.39" lower_limit="-5.83" upper_limit="18.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change to Interleukin-1 Alpha Receptor</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change to Interleukin-1 Alpha Receptor</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0005" lower_limit="-0.0007" upper_limit="0.0006"/>
                    <measurement group_id="O2" value="0.0197" lower_limit="-0.0014" upper_limit="0.0408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change to Interleukin-1 Beta Receptor</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change to Interleukin-1 Beta Receptor</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" lower_limit="-0.011" upper_limit="0.044"/>
                    <measurement group_id="O2" value="0.027" lower_limit="-0.058" upper_limit="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Monocyte Chemotactic Protein 1</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Monocyte Chemotactic Protein 1</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" lower_limit="-0.084" upper_limit="0.028"/>
                    <measurement group_id="O2" value="-0.004" lower_limit="-0.026" upper_limit="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Quinone Oxidoreductase 1 Gene</title>
        <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ppm Oral Silver</title>
            <description>ASAP Solution 10 ppm: Silver nanoparticles at 10ppm</description>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
            <description>ASAP Solution 32 ppm Diluent: Silver nanoparticles at 32ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quinone Oxidoreductase 1 Gene</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0043" lower_limit="-0.0115" upper_limit="0.029"/>
                    <measurement group_id="O2" value="-0.0279" lower_limit="-0.4671" upper_limit="0.4114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>10ppm Oral Solution</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        </group>
        <group group_id="E2">
          <title>32ppm Oral Solution</title>
          <description>All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Munger, Pharm.D.</name_or_title>
      <organization>University of Utah</organization>
      <phone>8015816165</phone>
      <email>mmunger@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

